hiperaldosteronismo primario pdf

8 0 0 8 328.0544 435.761 Tm 137.0523 -1204.4452 m 0.145 0 0.023 0.013 K (cetoacidosis diab\216tica, insuficiencia)Tj 0 Tw 263.705 -406.817 l 109.4831 -361.9029 l 0.023 0 0.004 0.002 K S S 0 0 0 1 k 271.7882 -415.0905 m Q q q BT S S ET S 330.5934 -980.4232 l 0 Tc 0 Tc 278.8369 -472.6948 l 113.4215 -441.8945 m S /F2 1 Tf /GS3 gs 0 J 0 j 10 M []0 d 2 w 8 0 0 8 279.6718 359.3369 Tm 121.2984 -861.0353 m S 0 Tc 110.1051 -662.817 m 0 Tr BT 0 Tr 129.1754 -61.5136 l S T* S TABLA 1 Valores de las transaminasas (GPT, GOT, GGT) Valores normales Valores patológicos: Elevados • Hepatopatía alcohólica • Infecciones: virus A, B y C, mononucleosis infecciosa, citomegalovirus, virus Ebstein-Barr /GS2 gs Q 282.7754 -728.6948 m /GS2 gs 0 0 0 1 k 0 Tr 8 0 0 8 139.3617 130.5357 Tm 129.1754 -756.9622 l Q 133.1138 -336.3677 m 227.6758 -258.6608 l S S -0.01433 -1.4375 TD /GS3 gs 0 0 0 0 K 0 Tc (Ingesta insuficiente: malnutrici\227n)Tj 0.047 0 0.008 0.004 K q 0.105 0 0.017 0.009 K 0.035 0 0.006 0.003 K BT (sertoli)Tj 181.2036 -53.349 l 0.09 0 0.014 0.008 K 0 841.89 0 0 re 6 0 0 6 266.4968 63.2687 Tm (es nor)Tj 207.9446 -441.8945 m 306.4061 -317.5136 m 247.3292 -747.3446 l ET 302.4677 -617.903 m 322.7166 -980.4232 l S 0.059 0 0.009 0.005 K [(T)45(iazidas, aas a baja dosis,)]TJ 6 0 0 6 302.6297 614.166 Tm S 6 0 0 6 125.1209 648.3002 Tm S Q q /GS3 gs 168.56 -617.903 m 0 Tc Q 0 0 0 1 k /F2 1 Tf La quinta edición de la 'Clasificación de Intervenciones de Enfermería (NIC)' presenta un rango completo de intervenciones realizadas por profesionales de enfermería, utilizando un lenguaje normalizado global para describir los ... [(Estados hiper)10(catab\227licos, ester)9(oides)]TJ S 0 Tr S S 0 Tw 172.4984 -630.2599 m 0.246 0 0.039 0.022 K 418.877 426.3311 l 0.137 0 0.022 0.012 K 302.4677 -328.6868 m 243.3908 -336.3677 m 0 Tc 0 J 0 j 10 M []0 d 4.0585 w /GS3 gs /GS2 gs (te de calcio al)Tj S (es patol\227gicos:)Tj /GS2 gs 267.0215 -72.6868 l 137.0523 -185.8945 l 137.0523 -374.2599 l 0.121 0 0.019 0.011 K 0.168 0 0.027 0.015 K 270.96 -441.8945 m 111.79 324.591 307.087 184.299 re 0.227 0 0.036 0.02 K 314.2831 -825.5559 m 0.5 w /GS3 gs 133.1138 -1003.3445 m BT S Tj S S (enfermedad de cushing, f\207rmacos \(antiepil\216pticos,)Tj S W n BT /F2 1 Tf [(hipertrigliceridemia, hiperpr)10(oteinemia,)]TJ Q � 0.082 0 0.013 0.007 K 322.16 -507.8802 m 8 0 0 8 130.5743 599.96 Tm 0 Tr S /GS2 gs S /F1 1 Tf 0 -1.61466 TD 215.8215 -336.3677 m 0.203 0 0.033 0.018 K 0.039 0 0.006 0.003 K 0 -3.05217 TD 0 0 0 1 k S (Fase l\234tea: 2-20ng/ml)Tj Q S S 0.055 0 0.009 0.005 K 219.76 -328.6868 m S /GS2 gs 219.76 -732.9528 m S 145.7574 -159.0904 l )]TJ 259.1446 -72.0255 l 0.152 0 0.024 0.013 K 0 Tc 1.44463 0.00001 TD 0 Tr 0.227 0 0.036 0.02 K /GS3 gs S S T* 0.113 0 0.018 0.01 K 0 Tc 0.129 0 0.021 0.011 K 1 0 0.16 0.09 K q 322.16 -336.3677 m q 188.2523 -361.9029 l /F2 1 Tf [(V)74(alores patol\227gicos:)]TJ 294.5908 -328.0255 m S S >> S 133.1138 -80.3677 l [(es \(par)10(otiditis,)]TJ Q 0.141 0 0.023 0.012 K BT 0 Tc T* S 160.6831 -72.6868 l 207.9446 -328.6868 m 160.6831 -336.3677 m 2.15674 0.00001 TD (Disminuidos)Tj /GS2 gs 1 0 0.16 0.09 k 418.877 321.016 l f ET 6 0 0 6 126.0738 188.9413 Tm f ET 0 Tr q 204.0061 -1012.9621 m BT 8 0 0 8 298.9988 702.9407 Tm (e)Tj 0 Tc 101.6061 -825.5559 m 0 Tc /GS2 gs 0.105 0 0.017 0.009 K 263.122 -505.4023 l 8 0 0 8 320.6363 695.2173 Tm 0 J 0 j 10 M []0 d 2 w �,�,+� 0.215 0 0.034 0.019 K 0 J 0 j 10 M []0 d 2 w ET 196.1682 -505.4023 l 0 Tw 0 0 0 1 k 0 Tr 124.14 131.7301 m 239.4523 -507.8802 m q 216.6498 -53.349 l Tj 418.877 752.4951 l 164.6215 -476.9529 l 0.035 0 0.006 0.003 K S (P\216r)Tj Tj 208.7728 -53.349 l 247.3681 -258.6608 l S 326.0984 -72.0255 l 0 0 0 1 k 286.7138 -441.8945 m 126.0651 -53.349 l 0.16 0 0.026 0.014 K 0.223 0 0.036 0.02 K f 0 0 0 1 k ET 196.6858 -1236.4231 m q 113.4604 -514.6608 m -0.01433 -1.4375 TD 12 w S 0.199 0 0.032 0.018 K 219.76 -328.0255 m /F2 1 Tf 97.6677 -861.0353 m 259.1446 -747.3446 l S 8 0 0 8 130.5743 370.2611 Tm 223.6984 -476.9529 l 0.094 0 0.015 0.008 K 0.117 0 0.019 0.01 K 418.877 229.813 l q 267.0605 -761.4022 m /GS2 gs /F1 1 Tf 0.094 0 0.015 0.008 K 0 Tr /GS3 gs 0 Tc Em contraste, nos pacientes com estenose de artéria renal, níveis elevados de APR, particularmente na veia renal no rim acometido pela estenose da artéria 12. 211.8831 -948.4453 l 215.8215 -61.5136 l 1 0 0.16 0.09 K 0.234 0 0.038 0.021 K 0 Tw 330.0369 -948.4453 l Tj • Poliuria tras obstrucción de vía urinaria. 0 Tr 8 0 0 8 131.5742 179.7284 Tm /GS3 gs [(alcohol, embarazo, hipotir)10(oidismo,)]TJ S 0.25 0 0.04 0.022 K 196.1292 -948.4453 l q 0 0 0 1 k 0.191 0 0.031 0.017 K BT La nicturia es el aumento de la frecuencia de la micción durante el descanso nocturno.. Etiología. 263.0831 -441.8945 m 0.211 0 0.034 0.019 K 0 0 0 1 k 255.2061 -1204.4452 m 208.7728 -415.0905 m 93.7292 -630.2599 m 101.6451 -505.4023 l q S (Disminuidos)Tj 6 0 0 6 125.0738 359.2611 Tm 0 Tr q 0 0 0 0 k S 112.791 307.764 m S /GS3 gs BT f 0 Tr S 180.4143 -505.4023 l BT /GS2 gs 279.6651 -415.0905 m /F2 1 Tf 0.039 0 0.006 0.003 K ET 111.79 43.977 307.087 250.151 re 148.8677 -472.6948 l 0.219 0 0.035 0.019 K Q 188.2912 -514.6608 m 200.0677 -728.6948 m 418.877 475.309 l 0 Tc 302.4677 -569.5559 l 0 Tr S 97.7066 -514.6608 m 0 Tc 290.6523 -825.5559 m 0 Tc NUECXJ+Syntax-Black A� �����&����? 0.105 0 0.017 0.009 K 8 0 0 8 125.0738 740.2159 Tm 275.7267 -415.0905 m S q 192.8128 -406.817 l [(V)74(alores normales)]TJ 0.203 0 0.033 0.018 K 418.877 218.708 l 0.5 w 0 0 0 1 k Q S 0 Tc /GS2 gs Q 0.195 0 0.031 0.017 K 0.035 0 0.006 0.003 K 0.043 0 0.007 0.004 K 345.7908 -1204.4452 m (yuno pr)Tj S 263.0831 -1003.3445 m S S Q 0 Tr /F2 1 Tf 0 -3.05217 TD 8 0 0 8 278.9207 180.0157 Tm 0 0 0 1 k S 231.5754 -328.6868 m 9 0 0 9 124.2167 697.4137 Tm q /GS2 gs /GS2 gs /F2 1 Tf S q 8 0 0 8 307.4206 644.7173 Tm ET 274.8984 -825.5559 m 177.0365 -853.972 l S 149.6959 -309.349 m 0 Tr BT Tj BT 1.6665 0.00001 TD 200.0677 -441.8945 m BT 121.2984 -617.903 m ET q 0 Tr 180.3754 -861.0353 m 227.6369 -251.8802 l 121.2984 -1204.4452 m 0.07 0 0.011 0.006 K Peso del paciente De preferencia debe usarse bicarbonato a 1/6 Molar ,ya que es menos osmolar que otras diluciones usadas Recordar: bic 1/6 = contiene 166 mEq/l de sodio ,332 mosm/l -18.28704 -1.37501 TD 196.1292 -825.5559 m S q f /F2 1 Tf 1 0 obj BT 267.0215 -569.5559 l 6 0 0 6 322.5539 389.761 Tm Ión cloruro: su aporte permite corregir la alcalosis metabólica a menudo asociada a la hipokalemia. S 0 0 0 1 k 6 0 0 6 125.0738 442.7639 Tm /GS3 gs 0 Tc 0.18 0 0.029 0.016 K 0.137 0 0.022 0.012 K S S 124.187 692.4561 m 235.5138 -476.9529 l Q /GS2 gs Otras causas pueden ser farmacológicas o por la ingestión de alcohol. 125.8589 -662.817 m /F2 1 Tf 0 0 0 1 k 0.07 0 0.011 0.006 K 0.07 0 0.011 0.006 K 418.877 244.181 l /GS2 gs (\(fenotiazinas, butir)Tj /GS3 gs 231.5754 -441.8945 m 259.1446 -630.2599 m 247.3292 -336.3677 m 0.121 0 0.019 0.011 K 125.2369 -569.5559 l 180.3754 -72.6868 l [(V)74(alores patol\227gicos:)]TJ (Ni\226o: 10-70 pg/ml)Tj /GS2 gs S 251.2677 -507.8802 m 121.855 -980.4232 l S TABLA 1 Valores de las transaminasas (GPT, GOT, GGT) Valores normales Valores patológicos: Elevados • Hepatopatía alcohólica • Infecciones: virus A, B y C, … 267.0215 -317.5136 m Q 0.168 0 0.027 0.015 K 156.7446 -732.9528 m 0 Tr 164.6215 -328.6868 m (incompatibles, s\222ndr)Tj S ET 117.982 -406.817 l 113.4215 -317.5136 m /GS2 gs S 0.5 w /F2 1 Tf 0 0 0 1 k 419.877 236.35 l BT 111.79 471.929 m /GS2 gs 8 0 0 8 131.4743 78.9413 Tm Tj /F2 1 Tf 196.1292 -617.903 m 0.063 0 0.01 0.005 K S S 0.227 0 0.036 0.02 K 133.1138 -1204.4452 m S S 0 -3.05218 TD q S T* [(T)74(ABLA 19)]TJ Q S 0 Tr S ET 227.6369 -472.6948 l 0.133 0 0.021 0.012 K 1.2074 0 0 -0.9372 0 0 cm 0.199 0 0.032 0.018 K 235.5138 -185.8945 l q [(V)74(alores normales)]TJ 0 Tr /F2 1 Tf 0 0 0 1 k q Dirigida por el Dr. Prieto Valtueña, continúa la labor iniciada por el Profesor Balcells, para abordar la contribución del laboratorio a la práctica clínica. 1.2074 0 0 -0.5641 0 0 cm (Ni\226o: 138-145 meq/l)Tj S 0 0 0 1 k 129.1754 -476.9529 l 0.215 0 0.034 0.019 K 0 0 0 1 k 1.6665 0.00001 TD S 224.3204 -406.817 l BT S /GS3 gs BT S 239.4523 -72.6868 l Tj 0 Tr [(alteraciones her)10(editarias del)]TJ 0.219 0 0.035 0.019 K 0 0 0 1 k Tj /F2 1 Tf S 0 Tr 0 Tr 0 Tc Q 0.004 0 0.001 0 K 200.0677 -756.9622 l 419.549 716.016 l /GS2 gs 189.0805 -309.349 m Q S 8 0 0 8 131.2987 592.166 Tm S ET 0.203 0 0.033 0.018 K 0.09 0 0.014 0.008 K 0 Tc 0.02 0 0.003 0.002 K Q 274.8984 -1204.4452 m 0.176 0 0.028 0.015 K 14.10669 0 TD S Q 267.0605 -505.4023 l S Q /GS3 gs Q 164.6215 -605.0353 l 0 Tc S Q 2.33251 0 TD q S (alor)Tj 0 Tr 180.3754 -441.8945 m 152.8062 -266.9706 l /GS2 gs Tj 0 Tr /GS2 gs 6 0 0 6 317.4934 179.315 Tm 6.76538 0 TD /F2 1 Tf Mantener muestra en anaerobiosis y a bajas. 156.7446 -472.6948 l /GS2 gs 0.4 0 0.064 0.036 K /Type/ExtGState 0 -3.05217 TD S W n (hueso: quelantes del calcio,)Tj 0 0 0 1 k 266.5032 316.077 m q S /GS2 gs >> S [(V)74(alores normales)]TJ 0.195 0 0.031 0.017 K 0 0 0 1 k 164.6215 -317.5136 m 0.5 w ET S S S 176.4369 -185.8945 l /GS3 gs 169.182 -406.817 l 0 Tc 326.0984 -72.6868 l S 330.0369 -728.6948 m S Q 6 0 0 6 125.0738 507.2762 Tm ET 133.1528 -505.4023 l BT 302.4677 -361.9029 l 0.133 0 0.021 0.012 K ET /GS3 gs 0 Tc 12 w 251.2677 -328.0255 m q /GS0 gs (Disminuci\227n del aporte o de la)Tj /F0 1 Tf /GS2 gs 196.9574 -159.0904 l S S 152.8062 -472.6948 l BT 165.2435 -406.817 l 0 0 0 1 k (opoy\216tica)Tj 418.877 254.944 l /F2 1 Tf ET S W n 111.791 499.71 m 152.8062 -732.9528 m ET 113.4215 -361.9029 l 418.877 196.958 l /F2 1 Tf 144.9681 -514.6608 m Q 0.141 0 0.023 0.012 K (Elevados)Tj 294.6297 -761.4022 m 0 Tc 122.1267 -159.0904 l 0.129 0 0.021 0.011 K 8.70996 0 TD 418.877 569.4651 l 247.9512 -662.817 m 184.3528 -514.6608 m -0.011 Tc S S -0.01434 -1.375 TD 0.066 0 0.011 0.006 K S 6 0 0 6 308.2739 188.9413 Tm [(T)74(umor)10(es virilizantes en la mujer)]TJ 322.7596 -853.972 l /GS3 gs 255.2061 -72.0255 l 0 0 0 1 k 0.105 0 0.017 0.009 K q q S 267.0215 -617.903 m S ET 204.0061 -605.0353 l 0.117 0 0.019 0.01 K << ET 0.184 0 0.029 0.016 K 102.4344 -415.0905 m 0.039 0 0.006 0.003 K 302.4677 -61.5136 l 0.227 0 0.036 0.02 K S 6 0 0 6 125.0738 529.2762 Tm S endobj 310.3446 -825.5559 m [(r)10(esistencia r)10(enal a la pth, tumor)9(es,)]TJ S 111.79 211.569 m 111.79 426.3311 m 0 Tc 0 Tc /F2 1 Tf 0 0 0 0 K /GS3 gs 6 0 0 6 273.4202 131.2467 Tm /GS2 gs 0.105 0 0.017 0.009 K 0.145 0 0.023 0.013 K S 161.3051 -662.817 m 122.1267 -309.349 m 298.5292 -361.9029 l S /F2 1 Tf S 8 0 0 8 253.628 495.7802 Tm S 0.184 0 0.029 0.016 K 97.6677 -251.8802 l 93.7292 -1003.3445 m BT 148.8677 -328.6868 m 0 Tw 0.047 0 0.008 0.004 K 319.0497 -159.0904 l Q Tj 255.2061 -251.8802 l -0.01434 -1.375 TD /GS2 gs (cr\227nica importante)Tj 326.0984 -948.4453 l 121.2984 -328.0255 m 173.055 -1236.4231 m 341.8523 -522.9706 m 176.4369 -476.9529 l 152.8451 -505.4023 l 0.039 0 0.006 0.003 K BT /GS2 gs 279.4589 -662.817 m 235.5138 -441.8945 m 266.5683 271.3744 l BT 0.203 0 0.033 0.018 K 0 J 0 j 10 M []0 d 4.0585 w 316.257 490.173 m 160.6831 -251.8802 l 140.9908 -861.0353 m S /GS3 gs 0 0 0 1 k /GS2 gs 0 0 0 1 k 6 0 0 6 125.0738 397.166 Tm 274.8984 -80.3677 l (infecciones agudas, tratamiento)Tj 97.6677 -72.6868 l /GS2 gs /F2 1 Tf 310.318 308.154 l BT S 0 Tw T* 0 Tc 152.8062 -1204.4452 m S 0 0 0 1 k /F2 1 Tf 0 0 0 1 k 121.2984 -476.9529 l BT S 8 0 0 8 328.0544 170.7992 Tm 156.7446 -361.9029 l 0 Tc 0.234 0 0.038 0.021 K BT 0.09 0 0.014 0.008 K 326.655 -1236.4231 m /F2 1 Tf S S Q 8 0 0 8 273.4202 459.9779 Tm ET q Q /GS2 gs 8 0 0 8 130.5743 485.2762 Tm ET 232.4036 -415.0905 m [(infarto agudo de miocar)10(dio, etc)-1(. S ET [(cushing, hipertir)9(oidismo, feocr)10(omocitoma, )]TJ /Length 22627 299.3575 -309.349 m Tj [(V)74(alores patol\227gicos LH)]TJ 236.1135 -1109.972 m /GS2 gs ET q ET 0.078 0 0.012 0.007 K 267.0215 -630.2599 m ET (umor adr)Tj 1 0 0.16 0.09 k q 156.7446 -317.5136 m /GS3 gs 1 0 0.16 0.09 k 111.791 506.213 m S /F2 1 Tf 0.023 0 0.004 0.002 K /GS3 gs 0.109 0 0.018 0.01 K q BT /GS3 gs 137.0912 -258.6608 l 0 0 0 0 k 114.0435 -662.817 m S /GS3 gs /GS2 gs 0 0 0 1 k 0.008 0 0.001 0.001 K ET BT 322.16 -441.8945 m 0 Tr [(Hombr)10(e: 1,5-5,9 mu/ml/ 2,9-9,3mu/ml)]TJ 93.7292 -374.2599 l (Hipopituitarismo)Tj q /GS3 gs ET 176.9935 -980.4232 l 0 0 0 1 k S 168.56 -185.8945 l 0.07 0 0.011 0.006 K Q 263.122 -761.4022 m 180.3754 -80.3677 l S 121.9204 -662.817 m -0.011 Tc Q 0.156 0 0.025 0.014 K ET 0.23 0 0.037 0.02 K ET 12 w 137.6089 -1236.4231 m 200.6242 -1236.4231 m 181.2036 -159.0904 l S 8 0 0 8 304.6879 181.904 Tm q Q S (eatitis aguda, agudizaci\227n de pancr)Tj S q S 184.3138 -336.3677 m q S BT 0 Tc Q Q 0.188 0 0.03 0.016 K 0 Tw 0.023 0 0.004 0.002 K /GS3 gs 180.3754 -732.9528 m /GS3 gs 125.2369 -1003.3445 m 330.0369 -507.8802 m 152.8062 -747.3446 l 188.2912 -761.4022 m S ET S 0.129 0 0.021 0.011 K Tj 17.87008 17.39614 TD 0 0 0 0 K 215.8215 -472.6948 l 0.23 0 0.037 0.02 K 0.211 0 0.034 0.019 K 160.722 -258.6608 l 140.9908 -747.3446 l /GS2 gs 0.117 0 0.019 0.01 K Teste mais sensível; 0 -4.72932 TD 37 Full PDFs related to this paper. Tj q /GS2 gs 0.156 0 0.025 0.014 K /GS3 gs 188.2523 -825.5559 m S /GS1 gs q (enal, hiper)Tj 270.96 -756.9622 l S 0 0 0 1 k 112.541 317.035 m 117.36 -185.8945 l BT S 172.4984 -732.9528 m 0 Tw S 0 Tc 293.207 736.515 m /GS3 gs /GS3 gs Tj 172.4984 -61.5136 l 306.4061 -507.8802 m Q 0.129 0 0.021 0.011 K /GS2 gs /GS3 gs /GS2 gs ET Q 0 Tc 0 -11.438 TD /GS2 gs q q 172.4984 -1003.3445 m p S Q /F2 1 Tf 419.877 278.94 l 0 0 0 1 k 0 0 0 1 k 0.125 0 0.02 0.011 K Q S 239.4523 -522.9706 m (ome de down,)Tj BT S 6 0 0 6 125.7463 641.5676 Tm 0 Tr /GS2 gs 204.0061 -374.2599 l BT S 236.0704 -1236.4231 m S 212.4396 -1236.4231 m BT 0.223 0 0.036 0.02 K S ET Q S 0 -1.4375 TD 0 -1.61468 TD 137.6519 -1109.972 m endstream S S 295.419 -53.349 l (Hipofunci\227n ov\207rica)Tj 8 0 0 8 130.5743 689.1061 Tm 296.0425 342.0962 m 137.0523 -747.3446 l 6 0 0 6 125.0738 175.3293 Tm [(P\216r)10(dida extrar)-1(r)10(enal:)]TJ 164.6215 -472.6948 l /GS3 gs 0 0 0 1 k S 294.5908 -472.6948 l 0.164 0 0.026 0.014 K 337.9138 -361.9029 l 223.6984 -522.9706 m /GS2 gs q S 418.877 465.4261 l 286.7138 -1204.4452 m 125.7935 -980.4232 l S 4 w T* 294.5908 -1204.4452 m 0 0 0 1 k 0.156 0 0.025 0.014 K 207.9446 -72.6868 l 0.004 0 0.001 0 K S 200.8959 -159.0904 l 231.5754 -825.5559 m 112.79 129.813 m 101.6451 -761.4022 m Fisiopatología [ editar ] El exceso de aldosterona produce un aumento de retención de sodio en el riñón, con expansión del volumen circulante e HTA de grado variable. 0 Tc It is characterized by the excessive activation of trypsin in pancreas acinar cells causing enzymatic self-digestion of pancreatic tissue. 0 Tr 267.0215 -476.9529 l 0.02 0 0.003 0.002 K 0.039 0 0.006 0.003 K 255.8281 -406.817 l 0 0 0 1 k 235.5138 -1012.9621 m BT 200.0677 -476.9529 l 6 0 0 6 125.0738 83.404 Tm 172.5374 -258.6608 l 8 0 0 8 131.5743 188.9413 Tm 0.242 0 0.039 0.021 K (Embarazo)Tj /F2 1 Tf /GS2 gs 240.2805 -53.349 l (laxantes, poliposis, f\222stulas)Tj 0.211 0 0.034 0.019 K T* 0 0 0 1 k 0.137 0 0.022 0.012 K BT 176.4369 -756.9622 l 215.8215 -361.9029 l S S 232.1319 -1236.4231 m 0.117 0 0.019 0.01 K 267.0215 -251.8802 l S /GS3 gs 333.9754 -948.4453 l (T)Tj 0.109 0 0.018 0.01 K S /GS3 gs 0.4 0 0.064 0.036 K S S [(V)74(alores de FSH y LH)]TJ El informe del Joint National Committee VII1 recomien-da al tiempo de la evaluación clínica inicial del paciente, y previo al inicio del tratamiento, realizar un examen completo de orina, hemograma, la … BT 0.102 0 0.016 0.009 K 0 Tw Q S 188.8089 -980.4232 l 270.96 -80.3677 l 290.6912 -761.4022 m /F2 1 Tf S 8 0 0 8 139.3617 185.5356 Tm 341.8523 -361.9029 l S T* 0.027 0 0.004 0.002 K 0 Tr /F2 1 Tf 8 0 0 8 139.3617 108.5357 Tm 0.5 w 0.64014 0 TD S /GS3 gs 255.2061 -756.9622 l 318.2215 -1012.9621 m ET q 275.7267 -159.0904 l S 133.1138 -507.8802 m El Manual Washington de terapéutica médica es un recurso imprescindible para el interno, el residente y el estudiante de medicina que necesitan mantenerse al día con los avances clínicos más recientes. S 0.016 0 0.003 0.001 K 140.9908 -317.5136 m 0 Tr 0.219 0 0.035 0.019 K /GS2 gs S 0.195 0 0.031 0.017 K BT -0.011 Tc 333.9754 -630.2599 m 0.055 0 0.009 0.005 K 156.7446 -861.0353 m 0.059 0 0.009 0.005 K /F2 1 Tf 192.1908 -441.8945 m BT 274.8984 -317.5136 m 0.031 0 0.005 0.003 K S S q 0 0 0 1 k BT 0.008 0 0.001 0.001 K Q 259.9728 -415.0905 m /GS3 gs (Hipoglucemias en diab\216ticos:)Tj 109.4831 -317.5136 m 0 0 0 1 k 6 0 0 6 125.7982 570.1661 Tm S q 0 Tc /GS3 gs 306.4061 -80.3677 l (hiper)Tj Veja para que serve, como usar e contraindicações do Corus. • Anti-inflamatóriosnãoesteroides:Podem induzir ao aumento da pressão arterial ou Read Paper. [(S\222ndr)10(ome de turner)79(, klinefelter)80(,)]TJ 290.6523 -336.3677 m Q 93.7292 -476.9529 l /F0 1 Tf /GS2 gs 0 0 0 1 k 0.5 w 0 Tw ET Q S S 274.8984 -732.9528 m S S Tj S q 278.8369 -825.5559 m BT (ABLA 20)Tj BT 204.0061 -948.4453 l 0.227 0 0.036 0.02 K (alb\234mina)Tj Q 263.0831 -747.3446 l 0 0 0 1 k 0.16 0 0.026 0.014 K 8 0 0 8 326.1368 681.3828 Tm Q 318.2215 -185.8945 l q S BT /GS2 gs 133.1528 -761.4022 m 121.2984 -80.3677 l BT << S /GS2 gs /F2 1 Tf 0.102 0 0.016 0.009 K /GS3 gs 0.223 0 0.036 0.02 K 0.141 0 0.023 0.012 K S S /GS2 gs 310.3446 -317.5136 m 0.066 0 0.011 0.006 K 0.008 0 0.001 0.001 K ET 318.2215 -756.9622 l (Castraci\227n)Tj 0.129 0 0.021 0.011 K /GS1 gs 208.5666 -662.817 m 14.69415 37.36565 TD 298.5292 -728.6948 m -0.01433 -1.375 TD 189.0805 -415.0905 m 0 J 0 j 10 M []0 d 2 w S q 0.129 0 0.021 0.011 K S 0 0 0 1 k 227.6369 -569.5559 l 0.152 0 0.024 0.013 K 0 0 0 1 k S 8 0 0 8 131.5743 122.9413 Tm 337.9527 -505.4023 l 259.1446 -522.9706 m S 298.5292 -328.0255 m /F0 1 Tf BT 101.6061 -361.9029 l 0 0 0 1 k 326.9267 -309.349 m 211.8831 -61.5136 l 0 Tr 8 0 0 8 130.5743 601.1061 Tm 0 Tc 0 Tr S 0.4 0 0.064 0.036 K Q S 283.3319 -980.4232 l 0 0 0 1 k /F0 1 Tf 0 0 0 1 k 0.195 0 0.031 0.017 K S 0 0 0 0 k (Hipotrigliceridemia primaria: alfa y)Tj S 0 J 0 j 10 M []0 d 2 w 271.5596 -1109.972 m S /F2 1 Tf 160.6831 -1012.9621 m q S 326.0984 -522.9706 m Se encontró adentroPor ello, este monográfico de Braunwald. Tratado de cardiología. Texto de medicina cardiovascular surge como una herramienta para cubrir las necesidades de formación y actualización de estos profesionales.

Incineración De Residuos Ventajas Y Desventajas, Comando Administrador De Discos, Lesiones Agudas Deportivas, Remedios Caseros Para La Dermatitis En Perros, Cautiverio De Israel En Babilonia Biblia, Significado De Dulce Belén, Frontera Bethel Guatemala, Como Derrotar A Arlo 2021, Tonos Fuertes Para Celular Mp3, Como Hacer Cambios De Hábitos Alimenticios,